DKK3 has been claimed to be downregulated in a broad range of cancers, such as non-small cell lung cancer (35), breast cancer (36, 37), gastric cancer (38), and melanoma (39), and this reduced expression was correlated with lower survival rates of patients from the respective cancer types. Here, DKK3 is linked to breast cancer.